Core Points - The legal opinion letter confirms the compliance of the 2025 Annual First Extraordinary General Meeting of YXTT Pharmaceutical Group Co., Ltd. with relevant laws and regulations [2][12] - The meeting was convened by the company's board of directors and followed the proper procedures as outlined in the company's articles of association [3][12] - The voting results indicate that all resolutions presented at the meeting were approved by a significant majority [6][12] Meeting Procedures - The meeting was convened based on a resolution from the 15th meeting of the 6th board of directors held on July 25, 2025 [2] - The notice for the meeting was published in major financial newspapers and online platforms on July 26, 2025 [2] - The meeting took place on August 12, 2025, in Kunming, Yunnan, with both on-site and online voting options available [3] Attendance and Voting - A total of 356 participants attended the meeting, representing 320,257,517 shares, which is 55.7815% of the total shares [5] - Among the attendees, 348 were small investors holding less than 5% of the shares, representing 38,471,623 shares [5] - The voting results showed that 99.9042% of the votes were in favor of the resolutions, with minimal opposition [6][12] Voting Results - The voting results for the resolutions were overwhelmingly positive, with significant support from both large and small shareholders [6][12] - Specific resolutions received votes such as 319,950,817 in favor, 242,400 against, and 64,300 abstentions [6] - The small investors' votes also reflected strong support, with 99.2028% in favor of the resolutions [6][12]

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于一心堂药业集团股份有限公司 2025 年度第一次临时股东会的法律意见书 致：一心堂药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及中国证券监 督管理委员会颁布的《上市公司股东会规则（2025年修订）》（以下简称"《股东 会规则》"）的规定，北京市竞天公诚律师事务所（以下简称"本所"）指派律师对 一心堂药业集团股份有限公司（以下简称"公司"）2025年度第一次临时股东会（以 下简称"本次股东会"）进行现场见证，并就本次股东会的有关事宜出具本法律意 见书。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法（2023）》和《律师事务所证券法律业务执业规则（试行）》等规 定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所 认定的事实真实、准确、完整，所发表的结 ...

一心为民 全心服务 一、会议召开和出席情况 股票代码：002727 股票简称：一心堂 公告编号：2025-069 号 （一）会议召开情况 一心堂药业集团股份有限公司 2025 年度第一次临时股东会暨中小投资者表决结果公告 1.召开时间： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会没有增加、否决或变更提案。 2.本次股东会不涉及变更前次股东会决议。 3.召开方式：现场投票及网络投票 4.召集人：本公司董事会 5.主持人：董事长阮鸿献先生。 6.会议通知于 2025 年 7 月 26 日刊登在《证券时报》《中国证券报》《证券日报》及巨潮 资讯网上。本次会议的召集、召开程序符合《中华人民共和国公司法》《中华人民共和国证券 法》《深圳证券交易所股票上市规则》以及《公司章程》的规定，会议合法有效。 （二）会议的出席情况 参加本次会议的股东、股东代表及委托投票代理人共有 356 人，代表股份 320,257,517 （1）现场会议时间：2025 年 8 月 12 日（星期二）下午 14 点。 （2）网络投票时间：2025 年 8 月 12 ...

Core Insights - The retail pharmacy industry is undergoing significant restructuring, with a net decrease of approximately 3,000 stores in the first quarter of this year, bringing the total number of retail pharmacies below 700,000 [1][10] - Smaller chains are struggling under competitive pressure, while those adapting to online retail strategies are finding new survival methods [1][10] Industry Trends - The number of chain pharmacies in China has increased from 170,000 to nearly 400,000, with a peak chain rate of 60.52% [2] - The competition has shifted from expansion to a focus on efficiency, service, and compliance due to new healthcare policies affecting profit margins [2][10] - The trend of "hive deep cultivation" emphasizes penetrating local markets rather than merely increasing the number of stores [2][10] Company Strategies - Companies like Yinpian Pharmacy have successfully implemented instant retail strategies, achieving significant online sales growth despite competition from larger chains [2][4] - The use of third-party platforms, such as Meituan, has become crucial for smaller chains, providing not only traffic but also essential operational tools [5][6] - Efficient supply chain management and internal training programs have allowed smaller chains to compete effectively with larger ones [6][7] Performance Metrics - In the first quarter, leading chain pharmacies reported over 10% year-on-year growth in instant retail performance, significantly outpacing traditional retail growth [10] - The average online retail business share for leading chains is around 8% to 10%, while smaller chains can range from 3% to 20% depending on their strategies [5] Future Outlook - The ongoing reshaping of the pharmacy sector suggests that survival will depend on finding niche markets and leveraging digital tools rather than competing on scale [10][11] - The ability to adapt to changing consumer behaviors and preferences will be critical for pharmacies aiming to thrive in a competitive landscape [11]

人民财讯8月12日电，企查查APP显示，近日，浙江一心堂（002727）心元界数智健康管理服务有限公 司成立，法定代表人为唐晓敏，注册资本为1000万元，经营范围包含：健康咨询服务(不含诊疗服务)； 食品销售(仅销售预包装食品)；养生保健服务(非医疗)等。企查查股权穿透显示，该公司由唐晓敏、一 心堂全资子公司一心堂健康管理有限公司等共同持股。 ...

一心堂药业集团股份有限公司 一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-068 号 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 第 1 页 共 2 页 一心为民 全心服务 本次保荐代表人变更后，公司持续督导期保荐代表人为朱海洲先生和周磊先生。根据《证 券发行上市保荐业务管理办法》《深圳证券交易所上市公司保荐工作指引》等相关规定，持续 督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义务结束为止。 公司董事会对于杨志先生在公司2018年度公开发行可转换公司债券持续督导期间所做出的 贡献表示衷心的感谢！ 特此公告。 一心堂药业集团股份有限公司 董事会 一心堂药业集团股份有限公司（以下简称"公司"）于2025年8月11日收到保荐机构东兴证 券股份有限公司（以下简称"东兴证券"）发来的《关于更换持续督导保荐代表人的函》。东 兴证券为公司2018年度公开发行可转换公司债券的保荐机构，截至目前，持续督导期已届满， 但公司募集资金尚未使用完毕，根据相关规定，东兴证券对此次未尽事项继续履行持续督导义 务。 东兴证券原指派的 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-068 号 一心堂药业集团股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）于2025年8月11日收到保荐机构东兴证 券股份有限公司（以下简称"东兴证券"）发来的《关于更换持续督导保荐代表人的函》。东 兴证券为公司2018年度公开发行可转换公司债券的保荐机构，截至目前，持续督导期已届满， 但公司募集资金尚未使用完毕，根据相关规定，东兴证券对此次未尽事项继续履行持续督导义 务。 东兴证券原指派的保荐代表人杨志先生因工作变动无法继续履行督导职责，为保证公司持 续督导工作的正常进行，东兴证券决定自2025年8月11日起委派朱海洲先生（简历附后）接替杨 志先生担任公司持续督导期保荐代表人，继续履行督导职责。 本次保荐代表人变更后，公司持续督导期保荐代表人为朱海洲先生和周磊先生。根据《证 券发行上市保荐业务管理办法》《深圳证券交易所上市公司保荐工作指引》等相关规定，持续 督导期至中国证券监督管理委员 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-067 号 一心堂药业集团股份有限公司 一、本次进行现金管理基本情况 二、投资风险分析及风险控制措施 1、投资风险 （1）公司现金管理属于低风险投资品种，但金融市场受宏观经济的影响较大，不排除该 项投资受到市场波动的影响； （2）公司将根据经济形势以及金融市场的变化情况适时适量介入资金，因此短期投资的 实际收益不可预期； 第 1 页 共 5 页 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元 ...

Core Insights - The retail pharmacy industry in China is experiencing a significant downturn, with an estimated 39,000 pharmacies expected to close in 2024, averaging 107 closures per day, and projections suggesting that closures could exceed 100,000 by 2025 [1][2] - Major players in the industry, such as Guoda Pharmacy and Jianzhijia, have reported substantial losses, with Guoda closing over 1,270 stores and incurring a net loss of over 1.1 billion yuan in 2024 [2] - The rapid expansion of pharmacies from 524,000 in 2019 to 667,000 in 2023 has led to market saturation, with the average number of customers served per store dropping from 4,112 in 2016 to 2,113 in 2023 [2][3] Industry Challenges - The high density of pharmacies has resulted in aggressive price competition, with many stores resorting to loss-leader pricing strategies to attract customers, ultimately harming their profitability [3] - Changing consumer habits, particularly among younger generations who prefer online channels for purchasing medications, have further exacerbated the decline in foot traffic to physical stores [3] - Tightening healthcare policies, including stricter regulations on insurance reimbursements and the shift of chronic disease medication distribution from pharmacies to community hospitals, have significantly impacted pharmacy revenues [3][4] Regulatory Environment - Starting in 2025, all participating pharmacies must implement drug traceability codes, complicating the procurement and settlement processes, which could increase operational costs for smaller pharmacies [4][5] - The requirement for licensed pharmacists to be present in all pharmacies by December 31, 2025, adds further compliance pressure, particularly for smaller operations [5] - The transition from a rapid expansion phase to a necessary industry adjustment reflects the need for pharmacies to focus on their role in public health rather than profit maximization [5]

Industry Overview - The retail pharmacy industry in China is experiencing a significant downturn, with an estimated 39,000 pharmacies expected to close in 2024, averaging 107 closures per day, and projections suggesting that closures may exceed 100,000 by 2025 [1][3] - The number of pharmacies surged from 400,000 in 2010 to nearly 700,000 by 2024, but this rapid expansion is now reversing [1][3] Company Performance - Major players in the industry, such as Guoda Pharmacy, have closed over 1,270 stores in 2024, reporting a net loss exceeding 1.1 billion yuan [3] - Other companies like Jianzhijia and Yibao Pharmacy have also reported significant losses, with Jianzhijia's profit dropping from 160 million yuan in 2023 to a loss of over 90 million yuan in 2024 [3] - In the first quarter of 2025, several pharmacies, including Yibao Pharmacy and Yifeng Pharmacy, have also announced store closures [3] Market Dynamics - The market is facing structural oversupply, with the average number of customers served per store dropping from 4,112 in 2016 to 2,113 in 2023, indicating a saturation of the market [3][5] - High competition has led to aggressive price wars among pharmacies, with many resorting to loss-leading promotions to attract customers, further straining their financial viability [5] Consumer Behavior - Changing consumer habits, particularly among younger generations, are shifting towards online platforms for purchasing medications, exacerbating the decline in foot traffic to physical stores [7] - The tightening of healthcare insurance policies, including stricter regulations on the use of insurance cards, has further reduced the profitability of pharmacies, particularly those relying on chronic disease medications [8] Regulatory Environment - New regulations requiring pharmacies to implement complex billing processes and maintain compliance with drug traceability have increased operational challenges, particularly for smaller pharmacies [8] - By the end of 2025, all pharmacies must employ licensed pharmacists, adding to the operational costs and compliance pressures faced by the industry [8]